About CLINUVEL

Mr Stanley McLiesh

BEd

Non-Executive Chair

 

Mr McLiesh has vast experience in commercializing pharmaceutical products internationally.

As the former General Manager, Pharmaceuticals at CSL Limited, he was closely involved in the transition of CSL from government ownership through corporatisation to a highly successful listed company. While at CSL, Mr McLiesh brokered numerous in-licensing agreements with international companies enabling CSL to expand into new markets profitably.

He has also been closely involved in a number of M&A transactions, the establishment of partnerships and collaborative relationships while he was the key professional to negotiate supply agreements for CSL's export products to international markets.

Mr McLiesh was formerly a non executive director of Unilife Medical Solutions Ltd. His considerable experience in the international pharmaceutical industry benefits CLINUVEL's international strategies.

In the latter stages of the development program Mr McLiesh is involved in formulating the commercial phase of CLINUVEL.

Latest Company Announcements

10 May 2017

Appendix 3B

Appendix 3B

Read More
10 May 2017

CLINUVEL Newsletter - May 2017

I look back at a turbulent period, as CLINUVEL has brought the ‘negotiations’ with GKV-Spitzenverband (National Association of Statutory Health Insurance Funds in Germany) to a successful end.

Read More
02 May 2017

NICE ENGLAND UPDATE ON SCENESSE®

CLINUVEL announce that the Department of Health has designated SCENESSE® to be evaluated as a Highly Specialised Technology (HST)

Read More
28 April 2017

Appendix 4C - Quarterly report

Appendix 4C

Read More
12 April 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
12 April 2017

CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board

CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board

Read More

Quick Links